Dr. Jay Patel joined the Eagle team in 2021 and has extensive experience in analytical chemistry and synthetic organic chemistry. Previously, he was the Manager of Research & Development and Quality Control at WDPrx, where he has successfully managed multiple NDA/ANDA projects from their inception to commercial launch by navigating them through the rough waters of regulatory agencies. Before his work at WDPrx, Jay spent time in academia as a Research Scientist at The University of Texas Medical Branch (UTMB), and as an Adjunct Assistant Professor of Chemistry at Fordham University and St. John’s University.
In Jay’s current role as the Vice President of Analytical Sciences, he leads a team of Chemists and Microbiologists to deliver efficient analytical testing for pharmaceutical finished products, raw materials, and components. The responsibilities of the position also involve managing cross-functional teams of relevant technical expertise to drive goal-oriented projects forward in a timely manner. He also acts as a consultant and subject matter expert to provide regulatory and technical guidance to clients. He leads the multidisciplinary efforts to streamline logistics and resources relevant to client specifics.
His formal education includes a Bachelor’s degree in Pharmacy, a Master of Science in Medicinal and Pharmaceutical Chemistry, and a Ph.D. in Medicinal Chemistry. During his free time, he likes to play cricket and biking. He also enjoys doing DIY projects around the house.
More from Dr. Jay Patel, Ph.D.
Bachelor’s of Science in Pharmacy – Gujarat University
2001-2005
Master’s in Medicinal & Pharmaceutical Chemistry – St. John’s University, NY
2006-2008
Ph.D in Medicinal Chemistry – Miami University
2009-2013
OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance – Biochemical Pharmacology
Jan 1, 2012
Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930 – Bioorganic & Medicinal Chemistry Letters
Jan 1, 2011
Polymethylhydrosiloxane (PMHS)/Trifluoroacetic acid (TFA):A novel system for reductive amination reactions – Tetrahedron Letters
Jan 1, 2009
Design, synthesis and evaluation of biological activity of Dasatinib analogues against Bcr/Abl, Abl T315I and Src protein tyrosine kinase as anticancer agents
Jan 2009 – May 2013
Design, synthesis and evaluation of OSI-930 analogues as dual inhibitors of c-kit and KDR tyrosine kinase
Jan 2006 – Dec 2008
Polymethylhydrosiloxane (PMHS)/Trifluoroacetic acid (TFA):A novel system for reductive amination reactions
May 2006 – Dec 2008
